Compare Illinois Tool Works Inc. (ITW) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Philip Morris International Inc. — how do they compare? Illinois Tool Works Inc. trades at $263.26 (market cap $74.38B), while Philip Morris International Inc. trades at $200.2 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 4× Illinois Tool Works Inc.'s market cap, and Philip Morris International Inc. pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and Philip Morris International Inc. for 85 Days on average.
| ITW | PM | |
|---|---|---|
Market Cap | $74.38B | $300.33B |
Volume | 1,125,477 | 3,935,700 |
Sector | Industrials | Consumer Staples |
52-Week High | $299.60 | $200.50 |
52-Week Low | $241.07 | $144.33 |
Typical Hold Time | 67 Days | 85 Days |
Enterprise Value | $83.23B | $343.44B |
Dividend Yield | 2.63% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $261.15, down 2.24% on the day, with a bearish technical signal from moving averages. The company demonstrates strong profitability with a 19.39% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights its status as a Dividend King, having raised its dividend to $1.72 per share, with a forward yield of approximately 2.57%.
The outlook is mixed; strong fundamentals and a consensus price target of $280.14 suggest upside potential, but a high P/E ratio of 23.65 and bearish technical indicators indicate near-term pressure. Key risks include economic sensitivity and rising debt levels, while institutional buying provides some support.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
